News & Activities » GenScript-Thermo Fisher Strategic Partnership on Life Sciences and Biopharma

GenScript-Thermo Fisher Strategic Partnership on Life Sciences and Biopharma

GenScript Biotech Corporation ("GenScript") a world leading bio-pharmaceutical CDMO company, and Thermo Fisher Scientific ("Thermo Fisher") announced their comprehensive partnership on life sciences and biopharma to promote the development of the whole biopharma industry chain from R&D to manufacturing. Under the agreement, Thermo Fisher will provide GenScript with quality services in terms of products, process optimization, supply chain optimization, training, and the development of the quality control system.

Signing Ceremony of GenScript-Thermo Fisher Antibody Drug Platform Strategic Partnership

GenScript has a leading and well-established platform covering the whole process from drug discovery to commercial manufacturing in China's biologics field, and has continuously increased capacities, building upon its leading position in biologics. In July 2019, GenScript held the opening ceremony of the biologics R&D and production center, representing a new milestone for biologics development. GenScript and Thermo Fisher have long-standing cooperation on life sciences, and will further develop a strategic partnership as GenScript expands into biologics customized development. The combination of Thermo Fisher's advanced products, technologies and services in the biopharma field and GenScript's powerful biologics customized development platform will contribute to standardized and efficient services and support the development of the biopharma industry.

Signing by executives of the parties

Tony Acciarito, President of Thermo Fisher China Division, said, "The upgrading of China's bio-pharmaceutical industry planning brings new development opportunities to China's anti-body drugs. I believe this strategic partnership will help China's bio-pharmaceutical enterprises to improve core competitiveness and facilitate the upgrading of China's healthcare industry through presence in both R&D and production."

Dr. Brian Min, CEO of GenScript BDBU, said, "We are excited about this strategic partnership with Thermo Fisher. The parties have common vision and cooperation willingness in the biologics field. GenScript has first-class quality management systems and powerful commercial manufacturing capacities. We are committed to accelerating the development of novel drugs based on advanced platforms and flexible business models, facilitating customers at home and abroad to make breakthroughs in the biologics field, and enabling rapid development of global biologics. We will partner with Thermo Fisher to build upon our advantages in biologics R&D and manufacturing, efficiently expand our capacities, cope with challenges, work on innovation and breakthroughs, and stay at the forefront of the industry."

In the future, as a world leader in the science service field, GenScript and Thermo Fisher will join hands to support China's bio-pharmaceutical industry and promote its industrialization and commercialization in China.